Achillion Pharmaceuticals Inc. has been purchased by Alexion Pharmaceuticals Inc. of Boston for $930 million, or $6.30 a share, pending approval by Achillion shareholders and regulators. Achillion shareholders will also get an extra dollar a share if the FDA approves Achillion’s Danicopan (for a rare blood disease) and another dollar if a drug in development
Twice during last year, Sanofi has come up short in high-stakes attempts at top M&A prospects. Now, the drugmaker has finally bagged an acquisition, though not on the scale of its runs for Medivation or Actelion. Sanofi said on Tuesday that it’s picking up Connecticut-based flu vaccine maker Protein Sciences in a deal worth $650
The global biopharmaceutical service provider, Parexel, is being snapped up by private equity group Pamplona Capital Management in a deal valued at approximately $5 billion (including debt) marking further consolidation of the contract research sector. The groups have signed a definitive agreement under which Pamplona will acquire all of the outstanding shares of Paraxel for
